Therefore, if we apply bDMARDS, which antagonizes TNF-α and IL-6, to inhibit inflammatory cytokine-induced proteolytic metabolism in a timely manner at an early stage of the disease, we can prevent the development of sarcopenia and OP. The gene discussed is IL6; the disease is sarcopenia.